Nurtec
(Rimegepant)ApprovedSmall molecule
PfizerRimegepant is used to treat acute migraine headaches, including the pain and other symptoms like nausea and sensitivity to light. It can also be used to prevent migraines from occurring in people who get them frequently.[2] Nurtec is currently approved and in use across 14 indications[4].[1]
Nurtec is one of 322 small molecule programs targeting Trigeminal Neuralgia. It is currently in Approved.
14
Indications
50
Total Trials
23
Active Trials
321
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Nurtec
PfizerApproved
Eylea
RegeneronPreclinical
Emend IV
Merck & Co.Preclinical
PORTRAZZA
Eli LillyPreclinical
Ketalar
AAultman Health Foundation
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Andriol
AAuxilium
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine36 trials
Show 33 more trials
A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06748664·240 enrolled
A Prospective Real World Study of Rimegepant in the Treatment of Migraine
Completed·—··NCT05709106·173 enrolled
ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
Active, not recruiting·—··NCT06439628·3,000 enrolled
Colorectal Cancer1 trial
Pancreatic Ductal Adenocarcinoma1 trial
10 more indications
Outcome1 trial
Temporomandibular Disorders1 trial
Headache1 trial
Unspecified1 trial
The R-E-V-I-V-A-L Study
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06992674·240 enrolled
Regulatory
FDA Approval Timeline[5]
Feb 27, 2020
NURTEC ODT
NDA NDA212728
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Nurtec drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Rimegepant. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Nurtec. U.S. Food & Drug Administration.
- [7]
- [8]